{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:10:02Z","timestamp":1791169802455,"version":"4.1.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T00:00:00Z","timestamp":1422489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s13311-015-0337-y","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T10:26:46Z","timestamp":1422440806000},"page":"303-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Spinal Muscular Atrophy Therapeutics: Where do we Stand?"],"prefix":"10.1016","volume":"12","author":[{"given":"Constantin","family":"d'Ydewalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte J.","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0337-y_bib1","doi-asserted-by":"crossref","unstructured":"Werdnig G. Zwei fruhinfantile heriditare Falle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. Arch Psychiatr Nervenkr, 1891.","DOI":"10.1007\/BF01776636"},{"key":"10.1007\/s13311-015-0337-y_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01668496","article-title":"Ueber chronische spinale Muskelatrophie im Kindesalter, auf famili\u00e4rer Basis","volume":"3","author":"Hoffmann","year":"1893","journal-title":"Deutsche Zeitschrift f. Nervenheilkunde"},{"key":"10.1007\/s13311-015-0337-y_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1007\/s13311-015-0337-y_bib4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy","volume":"152A","author":"Prior","year":"2010","journal-title":"Am J Med Genet"},{"key":"10.1007\/s13311-015-0337-y_bib5","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0337-y_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy. 2007","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","article-title":"The changing natural history of spinal muscular atrophy type 1","volume":"69","author":"Oskoui","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0337-y_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib10","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0337-y_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-015-0337-y_bib12","first-page":"291","article-title":"Progress and promise: the current status of spinal muscular atrophy therapeutics","volume":"12","author":"Van Meerbeke","year":"2011","journal-title":"Discov Med"},{"key":"10.1007\/s13311-015-0337-y_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/0883073807305669","article-title":"SMN transcript stability: Could modulation of messenger RNA degradation provide a novel therapy for spinal muscular atrophy?","volume":"22","author":"Heier","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.01262-08","article-title":"Regulation of SMN protein stability","volume":"29","author":"Burnett","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-015-0337-y_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2353\/ajpath.2007.070399","article-title":"Refined characterization of the expression and stability of the SMN gene products","volume":"171","author":"Vitte","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-015-0337-y_bib18","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/j.1460-2075.1996.tb00725.x","article-title":"A novel nuclear structure containing the survival of motor neurons protein","volume":"15","author":"Liu","year":"1996","journal-title":"EMBO J"},{"key":"10.1007\/s13311-015-0337-y_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0092-8674(00)80368-2","article-title":"The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis","volume":"90","author":"Fischer","year":"1997","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0092-8674(00)80367-0","article-title":"The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins","volume":"90","author":"Liu","year":"1997","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81632-3","article-title":"A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing","volume":"95","author":"Pellizzoni","year":"1998","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib22","doi-asserted-by":"crossref","first-page":"11167","DOI":"10.1073\/pnas.96.20.11167","article-title":"SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins","volume":"96","author":"Pellizzoni","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0337-y_bib23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1126\/science.1074962","article-title":"Essential role for the SMN complex in the specificity of snRNP assembly","volume":"298","author":"Pellizzoni","year":"2002","journal-title":"Science"},{"key":"10.1007\/s13311-015-0337-y_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2008.03.031","article-title":"SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing","volume":"133","author":"Zhang","year":"2008","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrm3742","article-title":"A day in the life of the spliceosome","volume":"15","author":"Matera","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1007\/s13311-015-0337-y_bib26","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1371\/journal.pone.0000921","article-title":"Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs","volume":"2","author":"Gabanella","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0337-y_bib27","doi-asserted-by":"crossref","first-page":"e1000773","DOI":"10.1371\/journal.pgen.1000773","article-title":"Alternative splicing events are a late feature of pathology in a mouse model of spinal muscular atrophy","volume":"5","author":"B\u00e4umer","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1007\/s13311-015-0337-y_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2012.09.012","article-title":"An SMN-dependent U12 splicing event essential for motor circuit function","volume":"151","author":"Lotti","year":"2012","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib29","doi-asserted-by":"crossref","first-page":"19348","DOI":"10.1073\/pnas.1319280110","article-title":"Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal muscular atrophy","volume":"26","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0337-y_bib30","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1523\/JNEUROSCI.23-16-06627.2003","article-title":"Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization","volume":"23","author":"Zhang","year":"2003","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0337-y_bib31","doi-asserted-by":"crossref","first-page":"8622","DOI":"10.1523\/JNEUROSCI.3967-05.2006","article-title":"Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons","volume":"26","author":"Zhang","year":"2006","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0337-y_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbrc.2010.02.158","article-title":"SMN and the Gemin proteins form sub-complexes that localise to both stationary and dynamic neurite granules","volume":"394","author":"Todd","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-015-0337-y_bib33","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/hmg\/ddt254","article-title":"Dilysine motifs in exon 2b of SMN protein mediate binding to the COPI vesicle protein \u03b1-COP and neurite outgrowth in a cell culture model of spinal muscular atrophy","volume":"22","author":"Custer","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib34","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1093\/hmg\/ddu350","article-title":"SMN regulates axonal local translation via miR-183\/mTOR pathway","volume":"23","author":"Kye","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib35","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0337-y_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","article-title":"The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(\u2013\/\u2013) mice and results in a mouse with spinal muscular atrophy","volume":"9","author":"Monani","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/hmg\/ddi078","article-title":"SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN","volume":"14","author":"Le","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-015-0337-y_bib39","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1242\/dmm.007245","article-title":"The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy","volume":"4","author":"Sleigh","year":"2011","journal-title":"Dis Models Mech"},{"key":"10.1007\/s13311-015-0337-y_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","article-title":"Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy","volume":"69","author":"Mentis","year":"2011","journal-title":"Neuron"},{"key":"10.1007\/s13311-015-0337-y_bib41","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","article-title":"Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy","volume":"17","author":"Kariya","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddr453","article-title":"Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy","volume":"21","author":"Ling","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/hmg\/ddm367","article-title":"Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy","volume":"17","author":"Murray","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","article-title":"Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice","volume":"29","author":"Kong","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0337-y_bib45","doi-asserted-by":"crossref","first-page":"e15457","DOI":"10.1371\/journal.pone.0015457","article-title":"Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy","volume":"5","author":"Ling","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0337-y_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1523\/JNEUROSCI.4496-09.2010","article-title":"Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice","volume":"30","author":"Ruiz","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0337-y_bib47","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ydbio.2011.05.667","article-title":"Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons","volume":"356","author":"Lee","year":"2011","journal-title":"Dev Biol"},{"key":"10.1007\/s13311-015-0337-y_bib48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/brain\/113.2.433","article-title":"Acute infantile spinal muscular atrophy. Muscle apoptosis as a proposed pathogenetic mechanism","volume":"113","author":"Fidzia\u0144ska","year":"1990","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0337-y_bib49","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/brain\/awf155","article-title":"Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord","volume":"125","author":"Soler-Botija","year":"2002","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0337-y_bib50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-008-0411-1","article-title":"Pathogenesis of proximal autosomal recessive spinal muscular atrophy","volume":"116","author":"Simic","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-015-0337-y_bib51","unstructured":"Fidzianska A, Hausmanowa-Petrusewicz I. Morphology of the lower motor neuron and muscle. In: Gamstorp I, Sarnat HB, editors. Progressive Spinal Muscular Atrophies. Raven Press, New York; 1984;55-89."},{"key":"10.1007\/s13311-015-0337-y_bib52","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/hmg\/6.11.1961","article-title":"Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system","volume":"6","author":"Battaglia","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib53","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","article-title":"The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy","volume":"7","author":"Burlet","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/hmg\/9.3.341","article-title":"Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III","volume":"9","author":"Jablonka","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/64.3.215","article-title":"Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function?","volume":"64","author":"Soler-Botija","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib56","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","article-title":"Temporal requirement for high SMN expression in SMA mice","volume":"20","author":"Le","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib57","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI57291","article-title":"Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy","volume":"121","author":"Lutz","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0337-y_bib58","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI72017","article-title":"Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation","volume":"124","author":"Kariya","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0337-y_bib59","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2125.2010.03843.x","article-title":"Riluzole pharmacokinetics in young patients with spinal muscular atrophy","volume":"71","author":"Abbara","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1007\/s13311-015-0337-y_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.107.123000","article-title":"Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis","volume":"322","author":"Bordet","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-015-0337-y_bib62","first-page":"568","article-title":"Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis","volume":"13","author":"Martin","year":"2010","journal-title":"IDrugs"},{"key":"10.1007\/s13311-015-0337-y_bib63","unstructured":"Dessaud E, Andre C, Scherrer B, et al. Results of a phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old spinal muscular atrophy patients. 2014 In: 18th Annual International Spinal Muscular Atrophy Research Group Meeting abstract book. National Harbor, Maryland, June 12-14, 2014."},{"key":"10.1007\/s13311-015-0337-y_bib64","doi-asserted-by":"crossref","unstructured":"Farooq F, Abadia-Molina F, MacKenzie D, et al. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Hum Mol Genet 2013;22:3415-24.","DOI":"10.1093\/hmg\/ddt191"},{"key":"10.1007\/s13311-015-0337-y_bib65","doi-asserted-by":"crossref","unstructured":"Rose FF Jr, Mattis VB, Rindt H, Lorson CL. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet 2009;18:997-1005.","DOI":"10.1093\/hmg\/ddn426"},{"key":"10.1007\/s13311-015-0337-y_bib66","doi-asserted-by":"crossref","unstructured":"Sumner CJ, Wee CD, Warsing LC, et al. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet 2009;18:3145-52.","DOI":"10.1093\/hmg\/ddp253"},{"key":"10.1007\/s13311-015-0337-y_bib67","doi-asserted-by":"crossref","unstructured":"Rindt H, Buckley DM, Vale SM, et al. Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of spinal muscular atrophy. Neuromuscul Disord 2012;22:277-85.","DOI":"10.1016\/j.nmd.2011.10.012"},{"key":"10.1007\/s13311-015-0337-y_bib68","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"10.1007\/s13311-015-0337-y_bib69","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib70","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-015-0337-y_bib72","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-015-0337-y_bib73","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib74","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2013.03.052","article-title":"Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy","volume":"544","author":"Somers","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-015-0337-y_bib75","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib76","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0337-y_bib77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ana.21449","article-title":"Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition","volume":"64","author":"Narver","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0337-y_bib78","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0337-y_bib80","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: Double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0337-y_bib81","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNI-VAL trial part II: A prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0337-y_bib82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0337-y_bib83","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-015-0337-y_bib84","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/nsmb851","article-title":"Regulated nucleosome mobility and the histone code","volume":"11","author":"Cosgrove","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"10.1007\/s13311-015-0337-y_bib85","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib86","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/hmg\/ddi205","article-title":"Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy","volume":"14","author":"Jarecki","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1021\/cb800120t","article-title":"DcpS as a therapeutic target for spinal muscular atrophy","volume":"3","author":"Singh","year":"2008","journal-title":"ACS Chem Biol"},{"key":"10.1007\/s13311-015-0337-y_bib88","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/hmg\/ddp510","article-title":"Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy","volume":"19","author":"Butchbach","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib89","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1093\/hmg\/ddt258","article-title":"The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models","volume":"22","author":"Gogliotti","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib90","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1093\/hmg\/ddt257","article-title":"The DcpS inhibitor RG3039 improves motor function in SMA mice","volume":"22","author":"Van Meerbeke","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib91","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2012.02.014","article-title":"Aartsma-Rus A. Splice modulating therapies for human disease","volume":"148","author":"Spitali","year":"2012","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0337-y_bib92","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ymthe.2005.08.022","article-title":"Correction of Pre-mRNA splicing by antisense U7 small nuclear RNAs","volume":"12","author":"Madocsai","year":"2005","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-015-0337-y_bib93","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","article-title":"Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy","volume":"18","author":"Baughan","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib94","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1074\/jbc.M209271200","article-title":"An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA","volume":"278","author":"Miyaso","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-015-0337-y_bib95","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/hmg\/ddu198","article-title":"Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models","volume":"23","author":"Osman","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib96","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol and Cell Biol"},{"key":"10.1007\/s13311-015-0337-y_bib97","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","article-title":"Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon","volume":"5","author":"Hua","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1007\/s13311-015-0337-y_bib98","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-015-0337-y_bib99","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse","volume":"21","author":"Porensky","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib100","doi-asserted-by":"crossref","first-page":"e62114","DOI":"10.1371\/journal.pone.0062114","article-title":"Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: Towards a treatment for spinal muscular atrophy","volume":"8","author":"Mitrpant","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0337-y_bib101","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1523\/JNEUROSCI.0950-09.2009","article-title":"Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy","volume":"29","author":"Williams","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0337-y_bib102","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"key":"10.1007\/s13311-015-0337-y_bib103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2012","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0337-y_bib104","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","article-title":"Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients","volume":"10","author":"Andreassi","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0337-y_bib105","doi-asserted-by":"crossref","first-page":"5ra12-2","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Science Transl Med"},{"key":"10.1007\/s13311-015-0337-y_bib106","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1007\/s13311-015-0337-y_bib107","unstructured":"Servais R, VanHoosear M, Cheung A, et al. Identification and characterization of a novel, orally available small molecule modulator of SMN2 splicing. 2014 In: 18th Annual International Spinal Muscular Atrophy Research Group Meeting abstract book. National Harbor, Maryland, June 12-14, 2014."},{"key":"10.1007\/s13311-015-0337-y_bib108","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-015-0337-y_bib109","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/mt.2011.157","article-title":"Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders","volume":"19","author":"Bevan","year":"2009","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-015-0337-y_bib110","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-015-0337-y_bib111","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2011.11.121","article-title":"Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of Spinal Muscular Atrophy","volume":"417","author":"Glascock","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-015-0337-y_bib112","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1089\/hum.2011.166","article-title":"Decreasing disease severity in symptomatic, Smn\u2212\/\u2212; SMN2+\/+, spinal muscular atrophy mice following scAAV9-SMN delivery","volume":"23","author":"Glascock","year":"2012","journal-title":"Hum Gene Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0337-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923008267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0337-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:35Z","timestamp":1761806555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923008267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1878747923008267"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0337-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spinal Muscular Atrophy Therapeutics: Where do we Stand?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0337-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}